RLFTY (MindMaze Therapeutics Holding) Short Percentage of Float


RLFTY MindMaze Therapeutics Holding SA RLFTY
11 GF Score
Price $0.42
! 2 Warning Signs
View Full Analysis

What is MindMaze Therapeutics Holding Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

RLFTY vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, MindMaze Therapeutics Holding's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MindMaze Therapeutics Holding Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MindMaze Therapeutics Holding's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where MindMaze Therapeutics Holding's Short Percentage of Float falls into.


RLFTY
11GF Score
MindMaze Therapeutics Holding SA RLFTY
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MindMaze Therapeutics Holding Business Description

Other Exchanges MMTXz:UKMMTX:Switzerland
Address Avenue de Secheron 15, Geneva, CHE, 1202
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
11GF Score

Get the complete analysis for RLFTY

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.42
Price